John McCain no longer receiving treatment for terminal brain tumor

August 24, 2018

(HealthDay)—Senator John McCain's long battle with brain cancer may be nearing an end, with his family announcing Friday that he will no longer receive treatment for the condition.

The 81-year-old Republican Arizona senator and hero of the Vietnam War had been undergoing treatment for an aggressive glioblastoma since July of 2017, The New York Times reported.

"Last summer, Senator John McCain shared with Americans the news our family already knew: He had been diagnosed with an aggressive glioblastoma, and the prognosis was serious," his family said in a statement. "In the year since, John has surpassed expectations for his survival. But the progress of disease and the inexorable advance of age render their verdict. With his usual strength of will, he has now chosen to discontinue medical treatment."

One cancer expert who's not involved in McCain's care outlined the senator's likely condition.

"We can speculate that Senator McCain is worse neurologically and made it clear, now or beforehand, that if that happened, he would elect to have only," said Dr. Michael Schulder, who helps direct neurosurgery at North Shore University Hospital in Manhasset, N.Y.

"If there is any silver lining in this cloud, it is that patients who die from [glioblastoma] rarely have severe pain," he added. "They gradually become less alert and most often die from pneumonia or sometimes from the direct effect of increased pressure on the brain. Palliative care can alleviate any discomfort that patients do feel."

McCain has been largely absent from Congress and Washington, D.C., since December, and sources told the Times that his family has gathered in Arizona, and death may be near.

His illness hasn't stopped McCain from being a political force, however. Earlier this year he criticized President Donald Trump after a summit meeting with Russian President Vladimir Putin, for example.

McCain is the son and grandson of four-star Navy admirals and as a soldier spent five years as a prisoner of war in Vietnam. Over the past few decades he charted a swift rise in politics, both as Arizona senator and as the 2008 Republican nominee for the Presidency against Barack Obama.

According to the American Cancer Society (ACS), glioblastomas "are the fastest growing" of a subcategory of brain tumor known as gliomas. "These tumors make up more than half of all gliomas and are the most common in adults."

Each year, almost 24,000 Americans will be diagnosed with a brain or , and nearly 17,000 die from these tumors each year, the ACS said.

Schulder explained that "the course of glioblastoma progression is very different from patient to patient. Based on the biology, some patients succumb to the disease within months, most live between one and two years, and some live for many years in good condition after diagnosis and treatment."

Dr. John Boockvar directs the Brain Tumor Center at Lenox Hill Hospital in New York City. Although he is not involved in McCain's care, he said that the senator's "survival is in line with expectations from the time of his diagnosis. These are difficult decisions for the family at this time. I would measure his survival in weeks, not months."

Explore further: Laser therapy increases survival in grim cancer diagnosis

More information: Michael Schulder, M.D.,vice chair, neurosurgery, North Shore University Hospital, Manhasset, and director, Northwell Health's Brain Tumor Center, Lake Success, N.Y.; John Boockvar, M.D., vice chair, neurosurgery, and director, Brain Tumor Center, Lenox Hill Hospital, New York City; The New York Times, Aug. 24, 2018

There's more on brain tumors at the U.S. National Cancer Institute.

Related Stories

Laser therapy increases survival in grim cancer diagnosis

August 23, 2018
People diagnosed with the aggressive brain cancer glioblastoma face a grim prognosis. Half die within 14 months of diagnosis.

An especially challenging brain cancer diagnosis

August 24, 2017
Most brain cancers start elsewhere in the body, but one particularly aggressive and uncommon form—glioblastoma—originates in the brain itself.

Vulnerability identified for subtypes of glioblastoma

November 30, 2017
Glioblastoma, the most common and aggressive form of brain cancer, typically fails to respond to treatment or rapidly becomes drug resistant. In a paper published online in the journal Cancer Cell on November 30, University ...

DNA becomes primary target in fight against glioblastoma

July 21, 2017
By exploiting a brain tumor's own biology, researchers at FIU's Biomolecular Sciences Institute (BSI) are hoping to destroy glioblastoma, a deadly brain cancer with no known cure.

Gene therapy trial shows promise in treatment of recurrent brain cancer

October 28, 2017
New data from a Phase I clinical trial led by Clark Chen, M.D., Ph.D., Lyle French Chair in Neurosurgery and Head of the University of Minnesota Medical School Department of Neurosurgery shows more than a quarter of patients ...

New hurdles as Republicans rush to reverse Obama health law

September 19, 2017
After falling one vote short this summer, US Republicans have revived efforts to overhaul Barack Obama's landmark health care bill, but skepticism Monday by some in President Donald Trump's party has imperiled the plan.

Recommended for you

Aspirin could play valuable role as additional treatment for cancer

September 26, 2018
Regular use of aspirin could help in the treatment of some cancers, finds a new review of 71 medical studies.

Lung cancer drug could be repurposed to target 'zombie' proteins linked to leukemia

September 25, 2018
A new study by scientists at the University of Liverpool highlights how a clinically-approved lung cancer drug could potentially be 'repurposed' to design new treatments for future cancer therapies.

A protein called vaccinia-related kinase 1 may help cancer establish itself in new areas of the body during metastasis

September 25, 2018
Sometimes negative results can point researchers in the right direction.

Combo therapy of prostatectomy plus radiotherapy may improve survival in prostate cancer

September 25, 2018
High-risk prostate cancer, that which has continued to grow but not yet metastasized, is commonly treated with combination therapies. Each method has pros and cons, but there is little clarity whether one might be more effective ...

Brigatinib becomes potential new first-line option for ALK-positive non-small lung cancer

September 25, 2018
Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for ...

Two studies describe improved approach to bone marrow transplant

September 25, 2018
Two recent studies in the journal Leukemia present a new approach for bone marrow donation and transplant that preclinical laboratory tests suggest could make the life-saving procedure safer and more effective for patients.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.